NASDAQ:CDIO - Nasdaq - US14159C1036 - Common Stock - Currency: USD
4.31
+0.06 (+1.41%)
The current stock price of CDIO is 4.31 USD. In the past month the price decreased by -68.47%. In the past year, price decreased by -79.26%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.83 | 323.41B | ||
AMGN | AMGEN INC | 13.41 | 149.70B | ||
GILD | GILEAD SCIENCES INC | 14.01 | 134.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.30B | ||
REGN | REGENERON PHARMACEUTICALS | 13.36 | 63.90B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.23B | ||
ARGX | ARGENX SE - ADR | 98.17 | 35.18B | ||
ONC | BEIGENE LTD-ADR | 6.16 | 25.99B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
NTRA | NATERA INC | N/A | 22.01B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.34B | ||
BIIB | BIOGEN INC | 8.06 | 18.69B |
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
CARDIO DIAGNOSTICS HOLDINGS
311 W. Superior Street, Suite 444
Chicago ILLINOIS US
Employees: 8
Phone: 18552269991
The current stock price of CDIO is 4.31 USD. The price increased by 1.41% in the last trading session.
The exchange symbol of CARDIO DIAGNOSTICS HOLDINGS is CDIO and it is listed on the Nasdaq exchange.
CDIO stock is listed on the Nasdaq exchange.
CARDIO DIAGNOSTICS HOLDINGS (CDIO) has a market capitalization of 7.50M USD. This makes CDIO a Nano Cap stock.
CARDIO DIAGNOSTICS HOLDINGS (CDIO) currently has 8 employees.
CARDIO DIAGNOSTICS HOLDINGS (CDIO) has a resistance level at 4.77. Check the full technical report for a detailed analysis of CDIO support and resistance levels.
The Revenue of CARDIO DIAGNOSTICS HOLDINGS (CDIO) is expected to grow by 854.55% in the next year. Check the estimates tab for more information on the CDIO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CDIO does not pay a dividend.
CARDIO DIAGNOSTICS HOLDINGS (CDIO) will report earnings on 2025-08-12.
CARDIO DIAGNOSTICS HOLDINGS (CDIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.13).
The outstanding short interest for CARDIO DIAGNOSTICS HOLDINGS (CDIO) is 2.71% of its float. Check the ownership tab for more information on the CDIO short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CDIO. The financial health of CDIO is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months CDIO reported a non-GAAP Earnings per Share(EPS) of -3.13. The EPS decreased by -317.33% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -47.67% | ||
ROE | -51.46% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 83% to CDIO. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -224.15% and a revenue growth 854.55% for CDIO